To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Longitudinal Associations Between Physical Health Conditions in Childhood and Attention-Deficit/Hyperactivity Disorder Symptoms at Age 17
University of Southampton, Southampton, United Kingdom.
University of Southampton, Southampton, United Kingdom; Solent NHS Trust, Southampton, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Hassenfeld Children's Hospital at NYU Langone, New York; University Child Study Center, New York.
Örebro University, School of Medical Sciences. Karolinska Institute, Stockholm, Sweden.ORCID iD: 0000-0002-6851-3297
University of Bordeaux, Bordeaux, France; INSERM, Bordeaux Population Health Center, UMR1219, Bordeaux, France; Centre Hospitalier Perrens, Bordeaux, France; Research Unit on Children's Psychosocial Maladjustment, Montreal, QC, Canada.
Show others and affiliations
2024 (English)In: Journal of the American Academy of Child and Adolescent Psychiatry, ISSN 0890-8567, E-ISSN 1527-5418, Vol. 63, no 2, p. 245-254Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: While evidence suggests significant cross-sectional relationships between Attention-Deficit/Hyperactivity Disorder (ADHD) and several physical health conditions, less is known about their longitudinal associations. We investigated the cumulative effect of childhood physical health conditions on ADHD symptoms at age 17, controlling for environmental factors, ADHD medication status and ADHD symptoms at age three.

METHOD: Using Millennium Cohort Study data (Weighted n=8,059), we assessed whether four physical health clusters (sensory, neurological, atopic, and cardio-metabolic) were associated with scores on the ADHD subscale from the Strengths and Difficulties Questionnaire at age 17. Environmental factors were grouped into five cumulative risk indices: prenatal, perinatal, postnatal environment, postnatal maternal wellbeing, and sociodemographic factors. Regression analyses determined whether each physical health cluster was associated with ADHD score while controlling for environmental factors, ADHD medication and earlier symptoms.

RESULTS: Sensory, neurological, and cardio-metabolic clusters were all significantly associated with ADHD symptoms (β range = 0.04-0.09, p < .001). The overall model explained 2% of the variance. This rose to 21% (ΔR2 = .06) after adjusting for confounders. The sensory (β = 0.06) and neurological (β = 0.06) clusters remained significant (R2 = .21, ΔR2 = .06) but the cardio-metabolic cluster was no longer a significant predictor.

CONCLUSION: Sensory or neurological conditions in childhood were associated with higher ADHD symptoms aged 17 after adjustment of confounders. This was not the case for atopic or cardio-metabolic conditions. These findings have implications for the care of children with sensory/neurological conditions and future research examining ADHD etiopathophysiology.

Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 63, no 2, p. 245-254
Keywords [en]
ADHD, ADHD medication, environmental factors, physical health
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:oru:diva-106998DOI: 10.1016/j.jaac.2023.06.016ISI: 001170723600001PubMedID: 37406771Scopus ID: 2-s2.0-85166351874OAI: oai:DiVA.org:oru-106998DiVA, id: diva2:1780517
Funder
EU, Horizon Europe, 965381Swedish Research Council, 2018-02599; 2022-01119The Swedish Brain Foundation, FO2021-0115
Note

Disclosure: Prof. Cortese has declared honoraria and reimbursement for travel and accommodation expenses for lectures from the following non-profit as-sociations: Association for Child and Adolescent Central Health (ACAMH), Canadian ADHD Alliance Resource (CADDRA), British Association of Pharma-cology (BAP), and from Healthcare Convention for educational activity on ADHD. Prof. Larsson has acknowledged financial support from the European Union's Horizon 2020 research and innovation programme under grant agreement number 965381, the Swedish Research Council (2018-02599; 2022-01119) and the Swedish Brain Foundation (FO2021-0115). Prof. Larsson has reported receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. Prof. Larsson is editor-in-chief of JCPP Advances. Dr. Cotton was funded by an ESRC/UKRI postdoctoral fellowship, Grant number: G108309 (October 2020-August 2022). Dr. Brandt has acknowledged financial support from the Academy of Medical Sciences. Prof. Galera and Mrs. Reed have reported no biomedical financial interests or potential conflicts of interest.

Available from: 2023-07-06 Created: 2023-07-06 Last updated: 2024-03-20Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Larsson, Henrik

Search in DiVA

By author/editor
Larsson, Henrik
By organisation
School of Medical Sciences
In the same journal
Journal of the American Academy of Child and Adolescent Psychiatry
Psychiatry

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 81 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf